Meghan T. Miller
Basel, BS 4070, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Angelman syndrome patient-derived neuron screen leads to clinical ASO rugonersen targeting UBE3A-ATS with long-lasting effect in monkeys.
Journal: Nucleic acids research
Published: February 10, 2025
Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS).
Journal: Journal of neurodevelopmental disorders
Published: January 17, 2023
AntimiR targeting of microRNA-134 reduces seizures in a mouse model of Angelman syndrome.
Journal: Molecular therapy. Nucleic acids
Published: August 17, 2021
Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities.
Journal: Nature reviews. Drug discovery
Published: May 18, 2021
Measuring What Matters to Individuals with Angelman Syndrome and Their Families: Development of a Patient-Centered Disease Concept Model.
Journal: Child psychiatry and human development
Published: September 04, 2020
Antagomir-mediated suppression of microRNA-134 reduces kainic acid-induced seizures in immature mice.
Journal: Scientific reports
Published: April 17, 2020
Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment.
Journal: Molecular psychiatry
Published: February 01, 2020
Agonist-mediated switching of ion selectivity in TPC2 differentially promotes lysosomal function.
Journal: eLife
Published: December 23, 2019
Electrophysiological Phenotype in Angelman Syndrome Differs Between Genotypes.
Journal: Biological psychiatry
Published: September 04, 2018
Proteomic analyses reveal misregulation of LIN28 expression and delayed timing of glial differentiation in human iPS cells with MECP2 loss-of-function.
Journal: PloS one
Published: June 01, 2018
Last Updated: 09/26/2026